knowledge -WSS

knowledge

author：focus 2025-10-02 13:14:18 - browse：6

Illumina building. -- biotech coverage from STAT — Adobe

LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to the U.S. genetic sequencing giant Illumina for closing its acquisition of cancer detection company Grail before clearing it with regulators.

The fine amounts to nearly 10% of Illumina’s annual global revenue, which is the most the European Commission can penalize a company under its merger regulations. The commission called Illumina’s actions “an unprecedented and very serious infringement” of the EU’s policies, including the “cornerstone” that regulators review deals that can alter the market.

The commission also issued what it called a symbolic fine of 1,000 Euros, or about $1,100, to Grail for what it said was the firm’s “active role” in the deal’s infringement of EU rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： NYU radiologists take on the challenge of expensive MRI machines

WSS

PBM reforms clear House panel

U.K. considers world's first use of meningitis vaccine to address gonorrhea

The creative science of coining drug names

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Morphosys mixed study results for blood cancer drug

focus

knowledge

Wikipedia

Medicare details structure of new drug price negotiation program

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Novel spinal cord stimulator treats paralysis without surgery

Duchenne breakthrough therapy leaves behind pioneering families

Astellas still sees hope in its gene therapy after four deaths

Dobbs anniversary: the lost opportunity of abortion as health care

The effects of a landmark ruling on DNA ownership are becoming clearer

New air purifier tech could be key to improving indoor air quality

Primary care doctor shortage won't be solved by free med school tuition

entertainment

Primary care doctor shortage won't be solved by free med school tuition

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Chemotherapy before breast cancer surgery might fuel metastasis

David Sabatini, ex

Empower primary care with adequate payments and technology

FDA's Woodcock to retire early next year

focus

focus

knowledge

entertainment